Rawa K. Ismail
YOU?
Author Swipe
View article: LIMITATIONS OF PET SCAN IN THE DETECTION OF DISTAL METASTASES OF BRONCHOPULMONARY CANCER
LIMITATIONS OF PET SCAN IN THE DETECTION OF DISTAL METASTASES OF BRONCHOPULMONARY CANCER Open
Introduction: Positron Emission Tomography (PET) scanning has become essential in staging bronchopulmonary cancer, offering superior accuracy in detecting both mediastinal lymph node involvement and distant metastases. However, despite its…
View article: Abstract 367: Physiologic steal in white matter structures of non‐flow limited cerebral hemispheres as evidenced by observations of acetazolamide challenge arterial spin labeling MR
Abstract 367: Physiologic steal in white matter structures of non‐flow limited cerebral hemispheres as evidenced by observations of acetazolamide challenge arterial spin labeling MR Open
Background Acetazolamide administration can allow for comparisons between cerebral blood flow (CBF) at baseline and after acetazolamide challenge to evaluate the cerebral vasculature. While effects of augmentation have been studied in vaso…
View article: Abstract 331: MR Steal Phenomenon Corresponds to Cerebral Angiogram Circulation Time
Abstract 331: MR Steal Phenomenon Corresponds to Cerebral Angiogram Circulation Time Open
Background Cerebrovascular reserve (CVR) is crucial for assessing hemodynamic impairment in patients with cerebrovascular steno‐occlusive disease. While catheter cerebral angiography is the gold‐standard for evaluating CVR and collateral c…
View article: Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021
Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021 Open
For the Dutch Melanoma Treatment Registry (DMTR), the Dutch Institute for Clinical Auditing foundation received a start-up grant from governmental organization The Netherlands Organization for Health Research and Development (ZonMW, projec…
View article: A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors
A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors Open
The efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma that develop brain metastases (BM) remains unpredictable. In this study, we aimed to identify prognostic factors in patients with melanoma BM who are tr…
View article: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC
Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC Open
Background Many studies have compared real-world clinical outcomes of immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC) with reported outcomes data from pivotal trials. However, any differences observed could be …
View article: End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study
End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study Open
PURPOSE: The introduction of immune checkpoint inhibitors and targeted therapies improved the overall survival of patients with advanced melanoma. It is not known how often these costly treatments with potential serious side effects are in…
View article: Medication Use and Clinical Outcomes by the Dutch Institute for Clinical Auditing Medicines Program: Quantitative Analysis
Medication Use and Clinical Outcomes by the Dutch Institute for Clinical Auditing Medicines Program: Quantitative Analysis Open
Background The Dutch Institute for Clinical Auditing (DICA) Medicines Program was set up in September 2018 to evaluate expensive medicine use in daily practice in terms of real-world effectiveness using only existing data sources. Objectiv…
View article: Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors Open
Recent results of patients with advanced melanoma treated with first-line BRAF-MEK inhibitors in clinical trials showed 5-year survival in one-third of patients with a median overall survival (OS) of more than 2 years. This study aimed to …
View article: Real-world data in cancer treatment
Real-world data in cancer treatment Open
This thesis addressed how the real-world population of patients with cancer differs from the trial population and how real-world data can be used in daily clinical practice to improve cancer care. Quality registries are a source of real-wo…
View article: Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study
Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study Open
This study shows lower effectiveness of anti-PD -1 monotherapy and ipilimumab-nivolumab in AM, with lower response rates, PFS and OS than CM. This group of patients should be prioritised in the development of alternative treatment strategi…
View article: Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer
Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer Open
Palbociclib dose reductions occurred in real-world practice similarly to the PALOMA-3 trial. Patients with dose reductions had no poorer outcomes compared to patients not requiring a dose reduction. Older patients treated with palbociclib …
View article: The unfavorable effects of <scp>COVID</scp>‐19 on Dutch advanced melanoma care
The unfavorable effects of <span>COVID</span>‐19 on Dutch advanced melanoma care Open
The COVID‐19 pandemic had a severe impact on medical care. Our study aims to investigate the impact of COVID‐19 on advanced melanoma care in the Netherlands. We selected patients diagnosed with irresectable stage IIIc and IV melanoma durin…
View article: Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases
Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases Open
Postapproval trials and patient registries have their pros and cons in the generation of postapproval data. No direct comparison between clinical outcomes of these data sources currently exists for advanced melanoma patients. We aimed to i…
View article: Real‐world outcomes of advanced melanoma patients not represented in phase <scp>III</scp> trials
Real‐world outcomes of advanced melanoma patients not represented in phase <span>III</span> trials Open
The aim was to provide evidence on systemically treated patients with advanced melanoma not represented in phase III trials to support clinical decision‐making. Analysis were performed on advanced melanoma patients diagnosed between 2014 a…
View article: Real-world outcomes of advanced melanoma patients not represented in phase III trials.
Real-world outcomes of advanced melanoma patients not represented in phase III trials. Open
10042 Background: A large proportion of patients with advanced melanoma is not represented in phase III clinical trials, due to ineligibility. Real-world efficacy evidence of immune- and targeted therapies in these patients is lacking. We …